LISA-TRACKER Duo Vedolizumab
Product Description
LISA-TRACKER Duo Vedolizumab is an enzyme linked immunoassay for the quantitative determination of Vedolizumab (anti-α4β7 integrin) and anti-Vedolizumab antibodies in human serum samples.
- Comprehensive menu in inflammatory diseases and oncology
- Validated on principle drug and biosimilars
- Ready to use reagents
- Standardised protocols from sample collection to result interpretation
- Automation ready – protocols available on several open platform ELISA systems
-
- Feagan BG et al. Induction and Maintenance Therapy with Vedolizumab, a novel biologic therapy for ulcerative colitis. Gastroenterology & Hepatology, 10, Issue 1, 2014.
- Feagan BG et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The new England journal of medicine, 369, 699-710, 2013.
- McLean LP et al. Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease. Immunotherapy, 4, 883-898, 2012.
- Rosario M et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Alimentary Pharmacology and Therapeutics, 2015.
- Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for crohn’s disease. The new England journal of medicine, 369, 711-721, 2013.
- Soler D et al. The binding specificity and selective antagonism of vedolizumab, an anti- α4β7integrin therapeutic antibody in development for inflammatory bowel diseases. The journal of pharmacology and experimental therapeutics, 330, 864-875, 2009.
- Product Code: LTV-005
- Number of Tests: 2 x 48
- Sample Type: Serum or plasma
- Sample Volume: 100 μL (following predilution)
- Assay Range: Vedolizumab: 2 – 60 μg/mL / Anti-Vedolizumab: 35 – 500 ng/mL
- Add to Enquiry Basket
Interested? Enquire now.
Add to Enquiry Basket
Related Products
| Assays | Certification | Platform | Clinical Area | Portfolio | RUO/IVD |
|---|---|---|---|---|---|
| LISA-TRACKER Vedolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER anti-Vedolizumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Infliximab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Adalimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Golimumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD | |
| LISA-TRACKER Duo Ustekinumab | CE Marked | Therapeutic Drug Monitoring | TDM | IVD |